Navigation Links
Study Suggests Invega Helps Patients With Schizophrenia Maintain,,,Symptom Control

tolerability for INVEGA in the treatment of patients with schizophrenia. In this study, participants were treated with flexible doses of INVEGA (3mg to 15mg once daily, with 9mg as the starting dose) after concluding their previous double-blind study treatment. The study population was segmented into three subgroups based on treatment experience during the previous six-week trials: placebo to INVEGA; INVEGA to INVEGA; and olanzapine to INVEGA.

Because there were more INVEGA active treatment groups in the short-term efficacy trials, most patients entering this OLE study had previously received short-term treatment with INVEGA. Patient groups receiving INVEGA in the short-term efficacy trials were shown to have significantly improved by the end of short-term treatment when they became eligible to enter the OLE study, both in symptoms and in functioning, compared to placebo. In total, 47 percent of patients completed the longer-term 52-week OLE study.

Efficacy analyses included change from baseline to end point in Positive and Negative Syndrome Scale (PANSS)* total score and the Personal and Social Performance (PSP)** scale, a measure of personal and social functioning.


    EFFICACY ASSESSMENTS



    PANSS



    - Improvements in PANSS total score in all treatment groups were observed



      over the first 12 weeks of the OLE study and were maintained throughout



      the remainder of the 52-week trial



    - Mean PANSS total scores improved from open-label baseline most notably



      in patients in the placebo-to-INVEGA group





    PSP Scale



    - The improvements seen in patient personal and social functioning during



      the six-week placebo-controlled trial, were maintained over the 52-week



      period.



"The pooled efficacy data suggest to me that long-term treatment with INVEGA helps to sustain symptom control and social function
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:11/21/2014)... Texas , Nov. 21, 2014  World Hemp ... containing low THC, announces they are now offering legal, ... to Charlotte,s Web type strains grown in medical marijuana ... other neurological disorders, such as Parkinson,s, MS, and spinal ... US laws to pass, because imported CBD Oil Is ...
(Date:11/21/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... to acquire 100% of QCR & Trio Diagnostics Limited, ... organization. The transaction closed on November 17, 2014. ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, ... dass die Europäische Arzneimittel-Agentur (European Medicines ... Orphan-Medizinprodukt an Palovarotene vergeben hat, den ... von Fibrodysplasia ossificans progressiva (FOP). FOP ... Krankheit, die von schmerzhaften, wiederkehrenden Episoden ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Ganey Associates, Inc. today announced a broad partnership with ... help measure and improve satisfaction and engagement among patients, ... on October 1, 2009. , HMA owns and operates ... licensed beds, in non-urban communities located throughout the United ...
... CHICAGO and PALO ALTO, Calif., Oct. 14 ... first of its PRECISE Clinical Studies (Pulsed Plasma ... Surgical HEaling) demonstrating that its PEAK PlasmaBlade® tissue ... post-operative wound drainage, narcotic consumption, thermal injury, wound ...
Cached Medicine Technology:Press Ganey Partners With Health Management Associates 2PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons' Clinical Congress 2PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons' Clinical Congress 3
(Date:11/24/2014)... 2014 Volpara Solutions announced today ... the 100th Annual Meeting of the Radiology Society ... (RSNA Booth 1752 – South Hall). Volpara Solutions ... the rest of its innovative suite of quantitative ... enable personalized measurements of volumetric density, patient-specific dose, ...
(Date:11/24/2014)... SweetDressy.com, a well-known dress supplier and leader in the ... Dresses. All these fresh items are offered at affordable ... special offer is valid until Dec. 20, 2014. Click ... working well in the fashion industry for years. They ... dresses may be the best products for many ladies ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis Global ... the Aspergillosis clinical trial scenario. This report provides ... trials on Aspergillosis. It includes an overview of ... per the site of trial conduction across the ... disease clinical trials by their phase, trial status, ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... Paramount Acquisition,Corp. (OTC Bulletin Board: PMQC, PMQCU, ... the filing of a third,amendment to the preliminary ... that was originally filed on June 18, 2007. ... meeting of,stockholders to be held to consider the ...
... Rendell,recently appointed Richard Snyder, M.D., senior vice president ... the state,s Chronic Care,Commission. Snyder took his oath ... other commission appointees during its first meeting. ... for Pennsylvanians,living with chronic health conditions such as ...
... Barcelona, Spain: One of the largest individual studies of the ... concluded that it makes no difference whether a woman drinks ... itself (ethyl alcohol) and the quantity consumed that is likely ... risk from drinking three or more alcoholic drinks a day ...
... A new study adds fuel to the debate over whether ... cancer. , The study, presented by Australian ... in Barcelona, found some evidence suggesting exercise might increase the ... study included 24,479 Australian women aged between 27 and 75, ...
... 27 Sagent Pharmaceuticals,Inc., a privately-held specialty ... $53 million Series A financing led by ... used primarily to fund near-term product,launches, product ... development, sales and marketing,manufacturing and distribution partnerships. ...
... Pa., Sept. 26 Kensey Nash Corporation,(Nasdaq: ... Ramius Capital Group,L.L.C. and its affiliates on August ... the,Company,s outstanding common stock, as reported by Ramius ... Control" under the Company,s equity,compensation plan. As a ...
Cached Medicine News:Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 4Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 3Health News:Wine, women and... spirits, beer and breast cancer risk 2Health News:Wine, women and... spirits, beer and breast cancer risk 3Health News:Study fuels debate over whether exercise and body size influence ovarian cancer risk 2Health News:Study fuels debate over whether exercise and body size influence ovarian cancer risk 3Health News:Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing 2Health News:Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares 2Health News:Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares 3Health News:Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares 4
... PDCs computer-generated Thermal Printing Wristbands and ... direct thermal and thermal transfer printers. ... activate a heat-sensitive thermal coating under ... printers use heat to transfer highly ...
... Wristbands and Tags print in mere ... transfer printers. Direct thermal printers use ... coating under the bands protective surface. ... transfer highly durable ink from a ...
... coded patient identification bracelets (wristbands) and/or ... at patient care areas throughout the ... identification and in creating a positive ... back to the patient through the ...
... secure band is desired for adults and where an ... appropriate. The design allows for two bands to be ... on the wrist and the second to be held ... This is particularly useful in a hospital situation wherea ...
Medicine Products: